EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy

Nan Wang, Xin-Yun Huang, Xu-Feng Jiang, Li Wang, Shu Cheng, Peng-Peng Xu, Lei Dong iD, Bin-Shen Ou-Yang, Rong-Ji Mu iD, Chen Li, Yan Zhao, Yan Feng und 3 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Nan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Rituximab, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Clinical Research Plan of Shanghai Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Newly diagnosed follicular lymphoma (FL) patients usually received first‐line rituximab‐based immunochemotherapy (R‐chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo‐free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R‐chemo or R2. With data of sequential PET/CT at the baseline, interim, and end‐of‐induction, treatment responses and survival outcomes were analyzed using Deauville scores at the interim and end‐of‐induction. Additionally, correlations between interim Deauville scores and baseline PET/CT parameters were explored. Conclusively, we revealed that Deauville 1–3 at the interim and end‐of‐induction showed lower disease progression within 24 months (POD24) and superior progression‐free survival (PFS) in R‐chemo and R2 cohorts. Also, patients with interim Deauville 1–3 exhibited reduced POD24 and favorable PFS as compared to those with interim Deauville 4–5/end‐of‐induction Deauville 1–3. Furthermore, total lesion glycolysis of baseline PET‐CT surpassed standardized uptake value and total metabolic tumor volume in predicting interim Deauville 1–3, with different optimal cutoffs of 2600 and 600 mL in the R‐chemo and R2 cohort. These findings underscored the potential of PET‐CT‐adapted strategies to achieve durable remission in FL undergoing rituximab‐based immunochemotherapy or immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularRituximabPositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedAdultImmunotherapy

Stichwörter der Autor:innen

follicular lymphomaimmunochemotherapyimmunotherapyinterim PET/CTtotal lesion glycolysis

Substanzen

Rituximab

Autor:innen und Institutionen

  • State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
  • Department of Nuclear Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Network & Information Center, Shanghai Jiao Tong University, Shanghai, China.
  • School of Life Sciences and Biotechnology, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, Shanghai, China.

ORCID-Profile: Lei Dong, Rong-Ji Mu, Wei-Li Zhao

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Clinical Research Plan of Shanghai Hospital Development Center

Zitieren

APA

Wang, N., Huang, X. Y., Jiang, X. F., Wang, L., Cheng, S., Xu, P. P., Dong, L., Ou-Yang, B. S., Mu, R. J., Li, C., Zhao, Y., Feng, Y., Dou, H. J., Zheng, Z., & Zhao, W. L. (2025). Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy. Hematological Oncology. https://doi.org/10.1002/hon.70012

Vancouver

Wang N, Huang XY, Jiang XF, Wang L, Cheng S, Xu PP, et al. Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy. Hematological Oncology. 2025. doi:10.1002/hon.70012

BibTeX
@article{Wang2025,
  author = {Wang, Nan and Huang, Xin-Yun and Jiang, Xu-Feng and Wang, Li and Cheng, Shu and Xu, Peng-Peng and Dong, Lei and Ou-Yang, Bin-Shen and Mu, Rong-Ji and Li, Chen and Zhao, Yan and Feng, Yan and Dou, Hong-Jing and Zheng, Zhong and Zhao, Wei-Li},
  title = {Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70012}
}
Kostenlos starten →